We have located links that may give you full text access.
English Abstract
Journal Article
[Dermatological implications of omalizumab, an anti-IgE antibody].
Revue Médicale Suisse 2015 April 2
The Omalizumab is a humanized anti-IgE monoclonal for which the extensive experience of its use in allergic asthma confirms its very good tolerance. By frequent association with asthma, atopic dermatitis is the first dermatological field has having tested this biological agent, unfortunately without convincing study at present. Surprisingly, this anti-IgE antibody is also reported as effective in certain non-IgE-mediated diseases including several dermatological indications. Since 2014, the Omalizumab got the indication in Europe for the treatment of chronic spontaneous urticaria after escapement to antihistamines. It also seems promising for prevention of anaphylaxis in mastocytosis and some refractory bullous pemphigoid.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app